

Index

Page numbers followed by 'f' indicate figures; page numbers followed by 't' indicate tables.

- 3PPP, 134f
- AAADC (aromatic amino acid decarboxylase), 97, 98f
- ABT089, 203
- acetylcholine (ACh),
in arousal pathways, 150, 152f
and blocked dopamine receptors, 93f
overactivity, 95
reciprocal relationship with dopamine, 92f
- acetylcholine-linked mechanisms, 202
- ACP 103, 200
- ACP-104, 129, 134f
- ACR16, 134f
- adipose tissue, insulin resistance in, 141, 144f
- adolescence
aggressiveness in, 179
removal of synaptic connections, 68
risperidone for treating psychotic disorders, 166
- affective blunting, 5
- affective flattening, as SSRI side effect, 110
- affective symptoms
dorsal vs. ventral regulation, 76f
mesolimbic dopamine pathway role in, 28
multiple disorders impacting, 15f
pharmacy, 182, 184f
in schizophrenia, shared with other disorders, 14
- aggressive symptom pharmacy, 181f
- aggressiveness, 10
multiple disorders impacting, 15f, 16f
in schizophrenic patients, 13
- agitation,
benzodiazepines for, 188
and receptor conformation, 132f
- agranulocytosis, clozapine and, 164
- akathisia
from aripiprazole, 175
nigrostriatal pathway dopamine deficiencies and, 31
- alanine-serine-cysteine transporter (ASC-T), glial, 34
- alogia, 5, 6t
- alpha 1 adrenergic receptors
atypical antipsychotic agents and, 139f
and sedation, 151f
- alpha-1 receptor, antagonism, 94f
- alpha-2 adrenergic receptors, atypical antipsychotic agents and, 139f
- alpha 2 antagonists, 168
- alpha-4 beta-2 nicotinic acetylcholine receptor, 203
- alpha-7-nicotinic cholinergic agonists, 202
- alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 40, 40f, 66f
synapses with, 67f
- Alzheimer's disease, 180
cognitive symptoms, 13
excitotoxicity and, 56, 57f
symptoms shared with schizophrenia, 12, 13, 13f
- amantadine, 194
- amenorrhea, 32, 90
- d-amino acid oxidase (DAO), 38f, 39

- amisulpride, 130, 134f, 135f, 176, 183
 - and cardiometabolic risk, 140t
 - clinical actions of, 125
 - and diabetes, 171
 - for negative symptoms in schizophrenia, 182f
 - pharmacological icon, 177f
 - and QTc prolongation, 171
- amoxapine (Asendin), 173, 174f
- AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) glutamate receptors, 64
 - and synaptogenesis, 62
- AMPA-kines, 199
- amphetamines, 44
 - and dopamine release, 26
 - response to emotional input, 78
 - and schizophrenia symptoms, 75, 77f
- amylin, 204
- anhedonia, 5, 6t, 30
- antagonists,
 - vs. inverse agonist, 105
 - vs. partial agonists, 132f
 - presynaptic, 199f
- anticholinergic agents
 - D2 antagonism and, 93f
 - side effects, 95
- antihistamines, 82
 - atypical, 96
 - administration frequency, 122
 - cardiometabolic risk and, 140t
 - cardiometabolic risk management, 145
 - hit-and-run receptor binding properties, 124f
 - hypothetical action over time, 125f
 - to improve schizophrenia symptoms, 109
 - pharmacological properties, 139f
 - and prolactin, 118f
 - properties, 119, 135f
 - and weight gain risk, 140t
 - avoiding sedation and enhancing long-term outcome, 155f
 - benzodiazepines to lead in or top off, 188f
 - best practices for monitoring and managing, 149f
 - cardiometabolic risk and, 137–150
 - combining two, 191
 - conventional, 91f
 - vs. atypical, 112f, 114f
 - D2 binding of, 123f
 - D2-receptor antagonist, 83
 - hypothetical action over time, 123f
 - muscarinic cholinergic blocking properties, 91, 95
 - pharmacological properties, 82–96
 - and prolactin, 118f
 - risk and benefits of long-term, 95
 - in use, 85t
 - as D2 dopamine receptor blockers, 27
 - first-generation, 83f, 96
 - high doses, 191f
 - links between binding properties and clinical actions, 136
 - low-potency, and dissociation, 124
 - “off-label” uses, 82
 - patient toleration of, 163
 - pharmacokinetics, 156–162
 - pharmacological properties, 162–179
 - prescribing information, 82
 - prophylactic, 192
 - receptor interactions for, 134
 - sedation as short-term tool, 152f
 - side effects and compliance, 153f
 - switching, 185, 187f
 - process to avoid, 187f
 - from sedating to nonsedating, 189f
- antisocial personality disorder, 13
- anxiety disorders
 - 5HT1A receptors and, 103f
 - quetiapine for, 168f
- anxious mood, 14
- anxious self-punishment, 3
- apathy, 3
 - histamine-1 with 5HT2C antagonism, 141f
- aripiprazole, 129, 130, 134f–136f, 158, 175, 183
 - and cardiometabolic risk, 140t
 - as CYP 2D6 substrate, 158, 159f
 - and diabetes, 171
 - dosage with carbamazepine, 161f, 162
 - pharmacological icon, 176f
 - raising levels of, 160f
 - and sedation, 184, 186f
 - switching from sedating agent to, 189
 - and weight gain risk, 140t
- aromatic amino acid decarboxylase (AAADC), 97, 98f
- asenapine, 122f, 200
- Asendin (amoxapine), 173, 174f
- asociality, 5, 6t
- assaultiveness, 10
- atorvastatin
 - impaired, in schizophrenia, 11
- attention deficit hyperactivity disorder (ADHD), 180
 - symptoms shared with schizophrenia, 14
- attitudes, hostile, 3
- atypical antipsychotic agents, 96
 - administration frequency, 122
 - cardiometabolic risk and, 140t

- cardiometabolic risk management, 145
- clozapine as, 163
- vs. conventional, 112f, 114f
- hit-and-run receptor binding properties, 124f
- hypothetical action over time, 125f
- properties, 119, 139f
 - and weight gain risk, 140t
- auditory hallucinations, 5
- autism, 180
 - cognitive symptoms, 13
 - irritability in children with, 181
 - risperidone for irritability, 166
- avolution, 5, 6t
- “awakening”, 164, 191

- benzamide antipsychotics, clinical actions of, 125
- benzodiazepines, 153, 155f, 180
 - for aggression management, 181f
 - for agitation, 188
 - injectable, 179
 - to lead in or top off antipsychotics, 188f
 - when switching antipsychotics, 189f
- bifeprunox (DU 127090), 129, 130, 134f–136f, 177
 - and cardiometabolic risk, 140t
 - and diabetes, 171
 - in metabolic pharmacy, 183
 - metabolized by CYP 3A4, 158
 - for obesity, 202
 - pharmacological icon, 178f
 - and sedation, 186f
 - sedation risk with, 184
- bipolar disorder. *See also* mood stabilizers
 - bifeprunox for treating, 178
 - depressed phase of, 169
 - olanzapine and, 165
 - risperidone effectiveness for, 167
 - symptoms shared with schizophrenia, 12, 13, 13f
 - ziprasidone for, 170
- blame, 3
- blonanserin, 122f
- blood pressure
 - monitoring, 146, 150f
- blunted affect, 6t
- blurred vision, from conventional antipsychotics, 92f
- BMJ-14802, 200
- body mass index (BMI), 142f
 - baseline measurement, 149f
 - monitoring, 150f
- borderline personality disorder, 13, 180

- brain. *See also* circuits
 - dopamine pathways in, 26f, 22–29
 - excitotoxicity in early development, 62f
 - insult and schizophrenia, 57
 - survival of wrong neurons, 59
 - focus on malfunctioning areas, 16
 - glutamate pathways in, 43f, 41–45
 - nucleus accumbens as pleasure center, 83
- brain circuits, and schizophrenia symptoms, 14
- brain damage, 180
- brain-derived neurotrophic factor (BDNF), 58
 - 5HT₆ receptors and, 201
 - genes coding for, 63f
 - and long-term memory formation, 99
 - and synapse formation, 62, 65f
- Brief Psychiatric Rating Scale, 7t
- burnout
 - of neuronal systems, 28
 - in schizophrenic patients, 54, 55f
- bupirone, 201

- calcium
 - excessive
 - and excitotoxicity, 58f
 - overexcitation and dangerous opening of, 55
- calcyon, genes for, 73f
- cannabinoid antagonists, 203
- carbamazepine (Equetro), 160
 - CYP450 3A4 and discontinuation, 162f
 - CYP450 3A4 induced by, 161f
 - antipsychotic agents and, 143f, 171
 - atypical antipsychotic agents and, 139, 140t
 - clozapine and, 164
 - low risk antipsychotic agents, 140t
 - olanzapine and, 165
 - receptors mediating, 139f
- cardiovascular disease
 - atypical antipsychotic agents and, 137
 - risk of, 142f
- cardiovascular side effects, of antipsychotic drugs, 95
- catabolic enzymes,
 - and dopamine breakdown, 21, 21f
 - and dorsolateral prefrontal cortex, 19f
 - genes for, 73f
- CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), 153f
- cerebral cortex,
 - antipsychotic agent binding to postsynaptic 5HT_{2A} receptors, 114f
 - aggressiveness in, 179
 - psychotic illness, symptoms shared with schizophrenia, 12, 13, 13f
 - risperidone for, 166

- chlorpromazine (Thorazine), 82, 85t
 cholecystokinin (CCK), 204
 chorea, dopamine hyperactivity in nigrostriatal pathway and, 31
 CHRNA (alpha-7 nicotinic cholinergic receptor), 72f
 circadian rhythms
 5HT7 receptors and, 103f
 Cl1007, 134f
 Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 153f
 clinical practice
 vs. clinical trials, 178
 symptom treatment, vs. disease treatment, 179
 Clopixol (zuclopenthixol), 85t
 clozapine, 136f, 157, 157f, 158, 184
 5HT6-antagonist properties of, 201
 for affective symptoms in schizophrenia, 183
 for aggression management, 180, 181f
 and antagonism of muscarinic cholinergic receptor, 146f
 augmenting, 191
 binding properties, 163f
 and cardiometabolic risk, 140t
 as CYP 2D6 substrate, 158, 159f
 dosage with carbamazepine, 161f, 162
 M3 receptors blocked by, 146f
 for negative symptoms in schizophrenia, 182f
 pharmacological icon, 163f
 pharmacological properties, 163
 potency, and dissociation, 124
 raising levels of, 160f
 rebound psychosis from discontinued, 185
 for sedation, 185
 for suicide reduction, 164, 184f
 for symptom reduction in psychosis, 179
 and weight gain risk, 140t
 cocaine,
 and dopamine release, 26
 as antipsychotic side effect, 95
 from conventional antipsychotics, 92f
 as SSRI side effect, 110
 cognitive functioning,
 5HT1A receptors and, 103f
 5HT2C receptors and, 103f
 dorsolateral prefrontal cortex (DLPFC) and, 18f, 27
 impaired, 153
 sedation and somnolence and, 154
 mesocortical prefrontal cortex and, 17f
 quantifying, 11
 in schizophrenia, shared with other disorders, 13, 14f
 serotonin receptors and, 99
 cognitive symptom pharmacy, 182, 183f
 “combos” (combination of medications)
 for schizophrenia, 190, 204
 for symptom reduction in psychosis, 179
 communication
 dysfunction of, 5
 inhibitors, 202
 conceptual disorganization, 3
 conduct disorder, 179
 connectivity, genes affecting, 58
 constipation
 from conventional antipsychotics, 92f
 and emotion and cognitive symptoms, 17f
 and schizophrenia symptoms, 15
 cortical arousal, neurotransmitters of, 152f
 cortical brainstem glutamate projection, 43f, 44f
 cortical pyramidal neurons
 inhibition by 5HT1A receptors, 103f
 cortico-striatal-thalamic-cortical (CSTC) loops, 46, 47f
 corticoaccumbens projections, NMDA glutamate receptor hypofunction in, 51f
 corticobrainstem glutamate pathways
 neurons, 45
 and NMDA receptor hypofunction
 hypothesis of schizophrenia, 42–45
 corticocortical glutamate pathways, 43f, 48–52
 NMDA receptor regulation of, 53f
 corticostriatal glutamate pathways, 43f, 46
 corticothalamic glutamate pathways, 43f, 46
 cross titration, 186, 187f
 getting caught in, 188f
 CX516, 199
 CX546, 200
 CX619/Org 24448, 200
 cyamemazine (Tercian), 85t, 96, 175
 pharmacological icon, 175f
 cyclic AMP (adenosine monophosphate), disruptions in, 70f
 d-cycloserine, 195, 197, 197f
 cytochrome P450 (CYP450) enzyme systems,
 156, 156f
 CYP450 1A2 substrates, 157, 157f
 and smoking, 158, 158f
 CYP450 2C9, 158
 CYP450 2C19, 157
 CYP450 2D6, 157, 158, 159f
 antidepressants as inhibitors, 160f
 genetic polymorphism for, 157, 157f

- in risperidone conversion to paliperidone, 159f, 160f
 - inhibitors, 161f
 - CYP450 3A4, 158
 - inducers, 160
 - types, 156
- d-amino acid oxidase activator (DAOA), 69f
- and NMDA receptor regulation, 68, 68f
- d-amino acid oxidase (DAO), 68, 69f
- DDC (DOPA decarboxylase), 20, 20f
- death. *See also* neurons, cell death
- premature
 - atypical antipsychotic agents and, 137
 - risk of, 142f
- delusions, 2, 4
- antipsychotic action to reduce, 179
 - mesolimbic dopamine pathway role in, 26
 - reduction with mesolimbic D2 receptor block, 90
- dementia. *See also* Alzheimer's disease
- behavioral disturbances, 181
 - poststroke, cognitive symptoms, 13
 - psychosis with, 166
 - symptoms shared with schizophrenia, 12, 13f
 - excitotoxicity for pruning, 56
- Depixol (flupenthixol), 85t
- depressed mood, 14
- 5HT1A receptors and, 103f
- depressive psychosis, 3
- diabetes mellitus,
- atypical antipsychotic agents and, 137
 - zotepine and, 172
- diabetic ketoacidosis (DKA), 143, 147f, 149f
- clozapine and, 164
 - olanzapine and, 165
 - risperidone and, 167
- 3-[(2, 4-dimethoxy) benzylidene] anabaseine (DMXB-A), 203
- DISC-1 (disrupted in schizophrenia-1), 59, 61, 64f
- genes for, 63f, 70f
 - and glutamate synapses strengthening, 62, 66f
 - and NMDA receptor regulation, 68f
 - and NMDA regulation, 71
 - and synapse formation, 62, 65f
 - and synaptic vesicle transport, 71
- disinhibition, 100
- disorganized/excited psychosis, 3
- disorientation, 3
- divalproex (Depakote),
- for schizophrenia, 190
 - adding to antipsychotic, 191f
- divine mission, 3
- DMXB-A {3-[(2, 4-dimethoxy) benzylidene] anabaseine}, 203
- Dolmatil (sulpiride), 85t, 96, 129, 130, 134f, 135f, 177
- clinical actions of, 125
 - pharmacological icon, 177f
- dopa decarboxylase (DDC), 20, 20f
- dopamine, 18, 72f
- 5HT2A antagonists stimulation of release, 105
 - and acetylcholine activity, 93f
 - acetylcholine release inhibition, 94
 - agonist actions at 5HT1A receptors and, 131
 - in arousal pathways, 150
 - brain pathways, 26f, 22–29
 - deficit in mesocortical projections to dorsolateral prefrontal cortex, 28
 - diverse levels in brain subsections, 29
 - dorsolateral prefrontal cortex regulation by, 19f
 - genes influencing, 19f
 - hit-and-run theory, 127f
 - interaction with serotonin, in nigrostriatal dopamine pathway, 107f, 111f
 - levels in untreated schizophrenia, 127f
 - neuronal tuning, 29
 - neurotransmission spectrum, 128f
 - untreated schizophrenia and after serotonin dopamine antagonist, 120f
 - pharmacologic mechanisms influencing, 19f
 - prolactin inhibition by, 117f
 - reciprocal relationship with acetylcholine, 92f
 - 5HT1A and 5HT2A receptor regulation, 99, 100
 - 5HT2C receptors and, 103f
 - serotonin inhibition of, 106f
 - serotonin receptors influence on, 105f
 - serotonin regulation of, 108f–110f
 - synthesis, 20f
 - termination of action, 21f
 - and thalamic filter, 48f
 - tuning output with serotonin 2A/dopamine-2 antagonists, 119
- dopamine D1-selective agonists, 202
- dopamine D2 partial agonists, 96, 128f, 129, 129f
- aripiprazole as, 175
- dopamine D2 receptor agonists, 128f, 129
- dopamine D2 receptors, 21
- antagonists, 83, 83f, 84f, 91, 96, 129
 - and anticholinergic agents, 93f
 - integrated theory of schizophrenia and, 88f
 - mesocortical dopamine pathway and, 85f
 - nigrostriatal dopamine pathway and, 86f

- dopamine D2 receptors, (*Contd.*)
 rapid dissociation of 122f
 tuberoinfundibular dopamine pathway and, 88f
 blockade in nucleus accumbens, 107
 continuous occupancy, 169
 conventional antipsychotic binding to, 119
 dilemma of blocking in all dopamine pathways, 90
 output, 129f
 presynaptic, 21, 23f, 24f
 rapid dissociation from, 119, 121
 side effects of unwanted blockade, 136
 somatodendritic, 25f
- dopamine D3 antagonists, 202
- “dopamine hypothesis of schizophrenia”, 27
- dopamine neurons, 105
- dopamine partial agonists (DPAs), 125, 127f, 180f
 for aggression management, 181f
 for cognitive function improvement, 182f
 in development, 134f
 development of new, 202
 for first-line treatment of schizophrenia
 positive symptoms, 179
 integrated theory of schizophrenia and, 132f
 on market, 134f
 in mesolimbic pathway, 130f
 for negative symptoms in schizophrenia, 182f
 and nigrostriatal pathway, 131f
 spectrum, 135f
 switching from SDA to, 190f
- dopamine receptors, 21, 22f
- dopamine transporter (DAT), 20, 21f, 22f
 and dorsolateral prefrontal cortex, 19f
- dopaminergic neurons, 20–22
 cognition regulation by, 27
 cognitive symptoms and, 18f
 dopamine deficit in mesocortical projections to, 28
 genes influencing, 19f
 information processing involving, 73
 mesocortical dopamine pathway, 29f
 mesolimbic dopamine pathways in schizophrenia, 85f
 regulation by dopamine and serotonin, 19f
 and schizophrenia symptoms, 15, 76f
 from histamine-1 receptor blockade, 95
- drug abuse, 179
 by schizophrenic patients, 90
 symptoms shared with schizophrenia, 13
- drug-induced parkinsonism, 86
- drug-induced psychoses, symptoms shared with schizophrenia, 12
- drug interactions, 162
- dry mouth
 from conventional antipsychotics, 92f
- dysbindin, 59
 genes coding for, 63f
 and glutamate synapses strengthening, 62, 66f
 and NMDA receptor regulation, 68f
 and NMDA regulation, 71
 and synapse formation, 62, 65f
 vGluT regulated by, 71
- dysconnectivity, 59
- dyskinesias, dopamine hyperactivity in nigrostriatal pathway and, 31, 32f
- dyslipidemia, 139
 aripiprazole and, 176
 atypical antipsychotic agents and, 137
 blood pressure monitoring, 146
 ziprasidone and, 171
 zotepine and, 172
- dystonia, nigrostriatal pathway dopamine deficiencies and, 31
- dystrobrevin-binding protein 1, 58
- efficacy, path to, 155f
- efficacy profile, 154f
- elderly
 risperidone for, 166
- EMD128130 (sarizotan), 134f, 202
- emotion
 amygdala response to input, 78
 brain component regulating, 16
 mesocortical prefrontal cortex and, 17f
 mesolimbic dopamine pathway role in, 28
 brain areas impacting, 75
- eplivanserin (SR 46349), 201
- ERB signaling system, neuregulin activation of, 71
- essential amino acids, 39
- Essential Psychopharmacology: The Prescriber's Guide* (Stahl), 162, 163
- excitatory amino acid transporters (EAAT), 33, 40f
 for glutamate takeup, 35f
- “excitotoxic hypothesis of schizophrenia”, 54
- excitotoxicity, 57f
 cellular events during, 58f–61f
 in early fetal brain development, 62f
 and glutamate systems, 55, 194
 and neuronal insult, 57
- executive dysfunction, 11
 impaired
 in schizophrenia, 11
 by mesocortical dopamine pathway, 27

- extrapyramidal symptoms (EPS), 121, 123f
 5HT2A antagonist to reduce, 105, 107
 absence with atypical antipsychotics, 125f
 D2 receptor blockage and, 86
 dopamine partial agonism and, 132f
 risperidone and, 166
 from unwanted D2 receptor blockade, 136
- fasting triglycerides
 antipsychotic agents and, 145f
 baseline measurement, 145, 149f
 monitoring, 150f
 quetiapine and, 169
 rapid elevation of, 141
 risperidone and, 167
 ziprasidone and, 171
- fear. *See also* anxiety disorders
 processing by amygdala, 77f
 excitotoxicity in early development, 62f
 insult and schizophrenia, 57
 survival of wrong neurons, 59
 insults in neurodegenerative theories of schizophrenia, 54f
- first-generation antipsychotic agents, 83f, 96
- fluoxetine (Prozac),
 metabolite of, 159
 olanzapine and, 165
- flupenthixol (Depixol), 85t
- fluphenazine (Prolixin), 85t
- fluvoxamine, 159, 200
- free radicals, 60f
 and neuron death, 56
 scavengers for excitotoxicity, 196f
- G protein-linked receptors, 103f
- GABA (gamma-aminobutyric acid), 44f, 72f
- GABA (gamma-aminobutyric acid) neurons,
 46, 47f
 for connecting serotonin and dopamine neurons, 105
 dopamine impact on, 48f
 release, 105f
- galactorrhea, 32, 90
- genes
 susceptibility, 58
 for schizophrenia, 63t, 73
- genetic programming, in neurodegenerative theories of schizophrenia, 54f
- glial alanine-serine-cysteine transporter (ASC-T), 34
 glutamine release from, 36f
 glycine from, 38
- glial d-serine transporter, 38f
- glial SNAT, 34, 36f, 38
- glucose
 monitoring fasting, 146
 agonist actions at 5HT1A receptors and, 131
 conversion to glutamine, 34, 35f
 system overactivity, 28, 55
 key pathways in brain, 43f, 41–45
 NMDA hypofunction hypothesis of schizophrenia and, 42–45
 NMDA receptor excitation spectrum by, 57f
 pharmacology, 194
 preventing release, 199f
 recycled and regenerated, 35f
 conversion to glutamine, 36f
 glutamine release from glial cells, 36f
 5HT1A and 5HT2A receptor effect, 115f
 regulation with 5HT1A, 113, 116
 role in schizophrenia pathophysiology, 33
 susceptibility gene effect on, 71
 synapses, convergence of susceptibility genes for schizophrenia on, 68
 synthesis, 33
- glutamate receptors, 39, 40f
 metabotropic, 39, 42f
 types, 41t
- glutamatergic corticostriatal projections,
 NMDA glutamate receptor hypofunction in, 51f
- glutaminase, 34, 36f
- glutamine
 glutamate conversion to, 34, 35f
 release from glial cells, 36f
- glutamine synthetase, 34
- glycine, 197, 197f
 from glial cells, 38
 from l-serine, 39
 production, 37
- glycine agonists, 195
- glycine transporters (GlyT1), 196
 inhibitors, 198f
- grandiose expansiveness, 3
- guilt, 14
 CYP450 enzymes in wall, 156
 GW742457, 201
- H1 histamine receptor, and weight gain, 137
- hallucinations, 2, 5
 5HT2A receptors and, 103f
 5HT2A receptors effect on glutamate release and, 113
 antipsychotic action to reduce, 179
 mesolimbic dopamine pathway role in, 26

- hallucinations (*Contd.*)
 - reduction with mesolimbic D2 receptor block, 90
 - serotonin receptors and, 99
 - voices in, 2
- haloperidol (Haldol), 85t, 91f, 95
- histamine,
 - in arousal pathways, 150, 152f
 - antagonism, 94f
 - atypical antipsychotic agents and, 139f
 - blockade of, 95
 - and sedation, 151f
- histamine-1, with serotonin-2C antagonist, and appetite stimulation, 141f
- "hit and run" binding, 121
- hostile belligerence, 3
- hydroxy-pyruvate (OH-pyruvate), 38f, 39, 69f
- 9-hydroxy-risperidone, 167. *See also* paliperidone
- 5-hydroxytryptophan (5HTP), 97, 98f
 - of mesolimbic dopamine pathway, 27
- hyperglycemic hyperosmolar syndrome (HHS), 143, 147f, 149f
 - clozapine and, 164
 - olanzapine and, 165
 - risperidone and, 167
- hyperinsulinemia, 137
- hyperprolactinemia, 90
 - 5HT2A antagonists and reduction of, 116
 - from unwanted D2 receptor blockade, 136
- hypothalamic nuclei,
 - dopamine pathway from, 26f, 33
- iloperidone, 122f, 200
- impulsivity, 13
 - NMDA receptor hypofunction affect, 46
 - schizophrenia and, 11, 73, 74f
- insomnia,
 - quetiapine for treating, 169
- insulin, blocking M3-cholinergic receptors to reduce, 146f
- insulin resistance, 139
 - atypical antipsychotic agents and, 144f, 149f
 - psychopharmacologist options for, 151f
 - quetiapine and, 169
 - risperidone and, 167
 - ziprasidone and, 171
 - zotepine and, 172
- integrated dopamine hypothesis of schizophrenia, 33, 35f
- interpersonal functioning, impaired, in schizophrenia, 78
- inverse agonists,
 - vs. antagonists, 105
- ion channel-linked receptors, 40
- ionotropic receptors, 40
- irritability, 14
- judgment, distortions in schizophrenia, 78
- kainite receptors, 40, 40f
 - and schizophrenia symptoms, 43, 194
- ketoconazole, 159
- lactation, 32
 - for schizophrenia, 190
 - adding to antipsychotic, 191f
- language, odd use of, 11
- lazaroids, as free radical scavenger, 196f
- life expectancy, of schizophrenic patients, 4
- ligand-gated ion channels, 40f
- lithium, 190
 - for affective symptoms in schizophrenia, 183
 - for suicide reduction, 183, 184f
- liver
 - CYP450 enzymes in, 156
 - insulin resistance in, 141, 144f
- long-term potentiation (LTP), 62, 66f
- low-potency antipsychotic agents, and dissociation, 124
- loxapine (Loxitane), 85t, 96
 - 5HT6-antagonist properties of, 201
 - pharmacological icon, 174f
- luxapine, 173
- LY 293558, 200
- "master switch", 41
- MDL 100907, 201
- Mellaril (thioridazine), 85t
- MEM3454, 203
- memantine, 194
- memory,
 - long-term formation, BDNF and, 99
- mental retardation, 180
- mesocortical dopamine neurons, 45
- mesocortical dopamine pathway, 26f, 27, 29f
 - and D2 antagonists, 85f
 - dopamine output and, 120f, 132f
 - and serotonin-dopamine antagonism, 113f
 - to ventromedial prefrontal cortex, 30f
- mesocortical prefrontal cortex
 - and emotion and cognitive symptoms, 17f
 - and schizophrenia symptoms, 15
- mesolimbic circuits
 - malfunctioning, and positive symptoms of schizophrenia, 15, 16
 - and positive symptoms of schizophrenia, 17f

- mesolimbic dopamine hypothesis, 28f
- mesolimbic dopamine pathway, 26, 26f, 27f, 29, 44f
- blockade of D2 receptor antagonists, 84, 84f, 91
 - blockade of D2 receptors, 83
 - dopamine output and, 120f, 132f
 - hyperactivity of, 35f
 - and thalamus, 51f
- mesolimbic pathway, dopamine partial agonist in, 130f
- mesoridazine (Serentil), 85t
- metabolic highway, 142f
- monitoring on, 149f, 150f
- metabolic pharmacy, 183, 185f
- metabotropic glutamate receptors (mGluRs), 39, 42f, 197
- mGluRs (metabotropic glutamate receptors), 39, 42f, 197
- mirtazapine, 200
- mitochondria, 61f
- modafinil, 202
- molindone (Moban), 85t
- monoamine oxidase (MAO),
- and dopamine breakdown, 21, 21f
 - 5HT_{2C} receptors and, 103f
 - serotonin receptors and, 99
- mood stabilizers, 160, 180. *See also* lithium
- for aggression management, 181f
 - for schizophrenia, 190
 - adding to antipsychotic, 191f
 - mesolimbic dopamine pathway role in, 26
 - reduction in, 5, 30
- motor activity
- as antipsychotic side effect, 95
 - disturbances, 2
 - dopamine and prevention of side effects, 124
 - nigrostriatal dopamine pathway to control, 31
- muscarinic-1 agonists, 203
- muscarinic-1 receptors
- atypical antipsychotic agents and, 139f
 - and sedation, 151f
- muscarinic 3 (M₃) antagonism, and antipsychotic agents, 147f
- muscarinic cholinergic receptors,
- antagonism of, 144
 - blockade from conventional antipsychotics, 92f, 91–95
 - blocking to reduce insulin release, 146f
 - antipsychotic agents and, 171
 - myocarditis, clozapine and, 164
- n-back test, 74f
- in schizophrenia, 75f
- N-methyl-d-aspartate (NMDA) glutamate system, development abnormalities, 28
- N-methyl-glycine, 196
- N-methyl loxapine, 173
- Navane (thiothixene), 85t
- nefazodone, 159
- Negative Symptom Assessment, 7t
- negative symptom pharmacy, 181, 182f
- nemonapride, 122f
- neuregulin, 59, 64f
- genes coding for, 63f
 - and glutamate synapses strengthening, 66f
 - and NMDA receptor regulation, 68f
 - and NMDA regulation, 71
 - and synapse formation, 62, 65f
- neurokinin antagonists, 203
- neuroleptosis, 30, 82, 83, 150
- neuroleptic-induced deficit syndrome, 84
- neuroleptic-induced tardive dyskinesia, 31
- neuroleptic malignant syndrome, 96
- neuroleptics, 83
- neurons,
- cell death,
 - excitotoxic mechanism and, 58f
 - glutamate activity and, 55
 - preventing in schizophrenia, 194 - dopaminergic, 20–22
 - sensitivity to calcium, 59f
- neuropsychological assessment batteries, 11
- neurotensin antagonists, 204
- neurotransmitters,
- of cortical arousal, 152f
 - glutamate as, 33
 - 5HT₆ receptors and, 103f
- nicotinic partial agonists (NPA), 203
- nigrostriatal dopamine pathway, 26f, 31, 32f
- antipsychotic agent binding to postsynaptic D2 receptors, 112f
 - and D2 antagonists, 86f
 - dopamine output and, 120f, 132f
 - and dopamine partial agonists (DPAs), 131f
 - serotonin-dopamine interaction, 107f
 - serotonin regulation of dopamine release, 108f
- NMDA (N-methyl-d-aspartate) antagonists, 194, 195f
- NMDA (N-methyl-d-aspartate) receptors, 40, 40f, 41, 44f
- enhancement of activity, 198f
 - excitation spectrum by glutamate, 57f
 - genes affecting, 58
 - and glutamate systems, 37, 38f

- NMDA (N-methyl-d-aspartate) receptors
(*Contd.*)
 hypofunction, 200
 hypofunction hypothesis of schizophrenia,
 44f, 45f, 69f, 70f, 72f
 and corticobrainstem glutamate pathways,
 42–45
 hypofunction in glutamatergic corticostriatal
 and corticoaccumbens projections, 51f
 long-term potentiation (LTP) triggered by,
 66f
 normal excitatory neurotransmission of, 56f
 production, 37
 regulation of corticocortical glutamate
 pathways, 53f
 requirements for active, 197, 197f
 susceptibility gene regulation of, 71
 synapses with, 67f
 and synaptogenesis, 62
 norepinephrine (NE). *See also* serotonin
 norepinephrine reuptake inhibitors
 (SNRIs)
 in arousal pathways, 150, 152f
 5HT_{2C} receptors and, 103f
 norepinephrine reuptake inhibition (NRI), 174f
 norepinephrine selective reuptake inhibitors
 (NRIs), 202
 norepinephrine transporter (NET),
 inhibition,
 by norquetiapine, 169
 norfluoxetine, 159
 norquetiapine, 168, 168f
 NRA0562, 122f
 nucleus accumbens,
 D₂ receptor blockade in, 107
 as pleasure center, 83
 and schizophrenia symptoms, 16, 75, 76f
 “number needed to harm”, 87, 171
 obesity,
 5HT_{2C} receptors and, 103f
 atypical antipsychotic agents and, 137
 blood pressure monitoring, 146
 peptide treatments for, 204
 serotonin receptors and, 99
 observation, for negative symptom
 identification in schizophrenia, 6, 8f
 olanzapine, 157, 157f, 164, 184
 5HT₆-antagonist properties of, 201
 and antagonism of muscarinic cholinergic
 receptor, 146f
 and cardiometabolic risk, 140t
 as CYP 2D6 substrate, 158, 159f
 and diabetes, 171
 M₃ receptors blocked by, 146f
 pharmacological icon, 165f
 potency, and dissociation, 125
 raising levels of, 160f
 for sedation, 185
 and weight gain risk, 140t
 OPC 4293, 129
 oppositional defiant disorder, 179
 and schizophrenia symptoms, 15
 Org 24292, 200
 Org 25271, 200
 Org 25501, 200
 Org 25573, 200
 osanetant (SR142801), 204
 paliperidone, 158, 159f, 160f, 167, 183
 pharmacological icon, 167f
 and sedation, 186f
 sedation risk with, 184
 parabrachial nucleus (PBN)
 dopamine pathway from, 26f, 33
 paranoia, 78
 paranoid projection, 3
 paranoid psychosis, 3
 drug-induced, 86
 dopamine agonists for treatment, 21
 nigrostriatal pathway dopamine deficiencies
 and, 31, 32f
 quetiapine for, 169
 vs. antagonists, 132f
 perceptual distortions, 2
 periaqueductal gray matter,
 dopamine pathway from, 26f, 33
 perospirone, 173
 pharmacological icon, 173f
 perphenazine (Trilafon), 85t
 pharmacodynamics, 156
 pharmacokinetics, 156
 phencyclidine (PCP),
 and schizophrenia symptoms, 43, 44, 194
 Pick's disease, cognitive symptoms, 13
 pimozide (Orap), 85t
 pipothiazine (Piportil), 85t
 pituitary
 regulation of prolactin secretion, 116
 SPA action in, 131
 pleasure
 mesolimbic dopamine pathway role in, 26, 30
 reduce ability to experience, 5
 pleasure center
 nucleus accumbens as, 83
 PNU 9639/OSU 6162, 134f
 polypharmacy, 190, 192f
 Positive and Negative Syndrome Scale, 7t

- poststroke dementia, cognitive symptoms, 13
- pramlintide, 204
- prefrontal cortex,
 - 5HT_{2A} receptor activation, in schizophrenia, 114
 - fetal development, and schizophrenia, 57
 - and schizophrenia symptoms, 15, 75
 - SPA action in, 131
- presynaptic 5HT_{1A} receptors, 102f
- presynaptic 5HT_{1B/D} receptors, 101f
- presynaptic antagonists, 199f
- presynaptic D₂ receptors, 22, 23f, 24f
- procognitive agents, D₁-selective agonists as, 202
- prodrome
 - negative symptoms, 6, 10f
 - amisulpride and, 177
 - atypical antipsychotic agents and, 118f
 - clozapine and, 163
 - conventional antipsychotic agents and, 118f
 - elevation, 90
 - inhibiting release, 32
 - inhibition by dopamine, 117f
 - olanzapine and, 165
 - quetiapine and, 169
 - rise in levels, 88f
 - risperidone and, 167
 - secretion regulation, 116
 - serotonin stimulation of, 117f
 - zotepine and, 172
- Prolixin (fluphenazine), 85t
- protease inhibitors, 159
 - glutamate for biosynthesis, 33
- psychosis, 1
 - acute, ziprasidone for, 170
 - antipsychotic action to reduce symptoms, 179
 - as associated feature in disorders, 3t
 - disorders requiring presence as defining feature, 2, 2t
 - mesolimbic dopamine pathway role in, 26
 - positive symptoms, 5t
 - quetiapine for, 169
 - rebound, from discontinued clozapine, 185
- psychotic depression, symptoms shared with schizophrenia, 12, 13f
- psychotic episode, 4
- psychotic illness
 - combination chemotherapies for, 204
 - misconceptions, 1
- pyramidal cells,
 - malfunctioning glutamate input into, 52
 - output and input, 49
- QTc prolongation, ziprasidone and, 171
- questioning, for negative symptom identification in schizophrenia, 8f
- quetiapine, 136f, 158, 168, 183
 - 5HT₆-antagonist properties of, 201
 - binding properties, 168f
 - and cardiometabolic risk, 140t
 - and diabetes, 171
 - dosage with carbamazepine, 161f, 162
 - pharmacological icon, 168f
 - potency, and dissociation, 124
 - for sedation, 185
 - switching to non-sedating agent, 189
 - and weight gain risk, 140t
- rapid dissociation, 119, 121, 122f, 124f
- rapid "off" time, 119
- reasoning. *See also* cognitive functioning distortions in schizophrenia, 78
- rebound psychosis, from discontinued clozapine, 185
- relapse,
 - after antipsychotic treatment, vs. side effects, 95
- remission
 - by schizophrenic patient, 54
- resentment, 3
- retardation, 3
- reward
 - blocking mechanisms, 84
 - in mesolimbic dopamine system, 90
 - mesolimbic dopamine pathway role in, 26, 30
- RGH188, 134f
- rimonabant, 203
- risperidone, 166, 183
 - and cardiometabolic risk, 140t
 - conversion to paliperidone, 159f, 160f
 - as CYP 2D6 substrate, 158, 159f
 - and diabetes, 171
 - pharmacological icon, 166f
 - potency, and dissociation, 124
 - raising levels of, 160f
 - and sedation, 184, 186f
 - for treating irritability, 181
 - and weight gain risk, 140t
- RGS4 (regulator of G-protein signaling), 71
 - genes for, 72f
- sarcosine, 196
- sarizotan (EMD128130), 134f, 202
- Scale for Assessment of Negative Symptoms, 7t
- scary faces, schizophrenic patient response to, 77f, 78
- Schedule for the Deficit Syndrome, 7t

- schizoaffective disorder,
 symptoms shared with schizophrenia, 12, 13f
- schizophrenia
 5HT2A receptors activation in prefrontal cortex, 114
 acquired vs. inherited, 56
 atypical antipsychotics to improve symptoms, 109
 best long-term outcomes, 154f, 155f
 bifeprunox for treating, 178
 cognitive symptoms, 13, 13t
 combination chemotherapies for, 204
 diagnosis, value of deconstructing, 18
 excitotoxicity and, 56, 57f
 fetal brain insult and, 57
 free radical scavengers, 196f
 genetic basis, 58
 glutamatergic treatments for, 196f
 ideal treatment of, 112
 integrated dopamine hypothesis, 33, 35f, 88f
 and dopamine partial agonists, 132f
 and hit-and-run actions, 127f
 and serotonin-dopamine antagonists, 121f
 mesocortical dopamine hypothesis of
 negative, cognitive, and affective symptoms of, 31f
 as more than psychosis, 3–7
 negative symptoms, 5, 5t, 6t
 causes, 14f
 observation to identify, 6, 8f
 primary and secondary, 7t
 in prodromal phase, 6, 10f
 questioning to identify, 8f
 reasons to measure, 7t
 scales for assessing, 7t
 shared with other disorders, 12
 neurodegenerative hypothesis, 54f, 52–56
 neurodevelopmental hypothesis, 62f, 64f–67f
 neuroimaging circuits in, 73
 neutral stimuli and, 78f
 NMDA receptor hypofunction hypothesis of, 44f, 45f, 42–45, 52, 69f, 70f, 72f
 patient responsiveness to antipsychotic treatment, 54
 positive and negative symptoms, 4f
 positive symptom pharmacology, 179, 180f
 positive symptoms, 4, 5t
 link to mesolimbic/nucleus accumbens area, 16
 shared with other disorders, 13f
 presymptomatic and prodromal treatment, 192, 193f
 progressive nature of, 52
 rapid clinical assessment, 9t
- risperidone effectiveness for, 167
 stages, 55f
 substance abuse incidence in, 30
 susceptibility genes for, 63t
 symptoms, 11f, 2–18, 75
 overlap, 12f
 shared with other illnesses, 12–18
 treatment, vs. disease treatment, 179
- ziprasidone for, 170
- schizophrenic patients
 life expectancy of, 4
 siblings of, 74
 n-back test in, 76f
 smoking and drug abuse by, 90, 203
 suicide in, 4
- sedation,
 antipsychotic agents and, 150–154
 avoiding, 152–153, 155f
 long-term avoidance, 153f
 quetiapine and, 169
 receptors mediating, 151f
 as short-term therapeutic tool, 152f
 vs. somnolence, 154f
 zotepine and, 172
- sedation pharmacology, 184, 186f
- seizures
 clozapine or zotepine and increased risk, 158, 164
 zotepine and, 172
- self-mutilation, 179
- Serentil (mesoridazine), 85t
- serial learning, impaired, in schizophrenia, 11
- d-serine, 195, 197, 197f
 production, 37, 38f, 39
- d-serine racemase, 39
- l-serine, glycine synthesis from, 39
- serotonin-2C antagonist, histamine-1 with, and
 appetite stimulation, 141f
- serotonin (5HT), 72f
 1A agonists or antagonists, 201
 effect on glutamate release, 115f
 5HT1D antagonist action by ziprasidone, 172
 5HT2A antagonist binding to 5HT2A
 receptor, and dopamine release, 112
 and D2 antagonists, 119
 hyperprolactinemia reduction, 116
 reduction of positive symptoms, 116f
 effect on glutamate release, 115f
 and positive symptoms improvement, 113–116
- 5HT2A-selective antagonists/inverse
 agonists, 200
 agonists or antagonists, 201
 functions, 103f

Cambridge University Press

978-0-521-71413-6 - Antipsychotics and Mood Stabilizers: Stahl's Essential Psychopharmacology, Third Edition

Stephen M. Stahl

Index

[More information](#)

- olanzapine and, 165
 - and weight gain, 137
- 5HT6 antagonists, physiological role, 201
- 5HT7 antagonists, 201
- 5HT21 receptors, agonism of, 135f
- dorsolateral prefrontal cortex regulation by, 19f
- interaction with dopamine, in nigrostriatal dopamine pathway, 107f, 111f
- production, 98f
- prolactin stimulation of, 117f
- regulation of dopamine release, 108f–110f
- synthesis and termination of action, 97
- termination of action, 99f
- serotonin agonists, and 5HT2A antagonists, 132
- serotonin-dopamine antagonists (SDA), 96, 97f, 121f, 180f
 - for aggression management, 181f
 - for cognitive function improvement, 182f
 - in development, 122f
 - for first-line treatment of schizophrenia
 - positive symptoms, 179
 - integrated theory of schizophrenia and, 121f
 - and mesocortical dopamine pathway, 113f
 - for negative symptoms in schizophrenia, 182f
 - new options, 200
 - switching to DPA, 190f
- serotonin partial agonists (SPAs), 96, 136f
 - atypical antipsychotic agents and, 131
- serotonin receptors, 97, 100f, 105
 - 5HT1A and 5HT2A, 99
 - 5HT1A autoreceptors, 102f
 - 5HT1A receptors, 105f
 - 5HT1B/D autoreceptors, 101f
 - 5HT2A antagonist reduction of EPS, 105–107
 - 5HT2A receptors, 105, 105f, 106f
 - antagonist reduction of negative symptoms, 108–112
 - 5HT3 receptors, 103f
 - 5HT6 receptors, 103f
 - 5HT7 receptors, 103f
 - postsynaptic, 97, 105
 - impact of, 98
 - possible functions, 103f
 - presynaptic, 97–105
- serotonin selective reuptake inhibitors (SSRIs), 110
 - fluvoxamine, 159, 200
- serotonin transporter (SERT), 97
 - gene for, 73f
- sertindole, 158, 173
 - 5HT6-antagonist properties of, 201
 - dosage with carbamazepine, 161f, 162
 - pharmacological icon, 174f
 - and QTc prolongation, 171
- siblings of schizophrenic patients, 74
 - n-back test in, 76f
- sigma-1 agonists/antagonists, 200
- “sigma enigma”, 200
- skeletal muscle, insulin resistance in, 141, 144f
- sleep
 - 5HT2A receptors and, 103f
 - quetiapine for improving, 168f
 - serotonin receptors and, 99
- SLV313, 129, 134f, 202
- SLV314, 129, 134f, 202
- SM13493/lurasidone, 122f
 - CYP450 1A2 and, 158, 158f
 - by schizophrenic patients, 90, 203
- somatodendritic autoreceptor, 98, 102f
- somatodendritic dopamine D2 receptors, 25f
- somnolence, vs. sedation, 154f
- spinophyllin, genes for, 73f
- SR 147778, 203
- SR 241586, 204
- SR141716 A, 203
- SR31742A, 200
- SSR 146977, 204
- SSR125047, 200
- SSR180711, 203
- SSR181507, 134f, 202
- SSR591813, 203
- Stahl, S.M., *Essential Psychopharmacology: The Prescriber's Guide*, 162, 163
- Stelazine (trifluoperazine), 85t
- striatum,
 - SPA action in, 131
- stroke, 180
 - excitotoxicity and, 56, 57f
- substance abuse. *See also specific substance types*
 - incidence in schizophrenia, 30
- substance P antagonists, 203
- substantia nigra, 31
 - in schizophrenic patients, 4
 - attempts, 179
 - clozapine to reduce, 164, 183, 184f
 - sulpiride (Dolmatil), 85t, 96, 129, 130, 134f, 135f, 177
 - clinical actions of, 125
 - pharmacological icon, 177f
- superiority, attitude of, 3
- susceptibility genes, 58
 - for schizophrenia, 63t, 73
- switching antipsychotic agents, 185, 187f
 - process to avoid, 187f
- symptom domains, localization of, 15

- synapses,
 strength of, and survival or elimination, 67
 abnormal, 61
 genes causing, 65f, 66f
 from gene expression, 58
- talnetant, 204
- tandospirone, 201
- tardive dyskinesia, 86, 87f, 95, 123f
 clozapine and, 163
 neuroleptic-induced, 31
 reversal, 87
 from unwanted D2 receptor blockade, 136
- TC1827, 203
- tension, 14
- Tercian (cyamemazine), 85t, 96, 175
 pharmacological icon, 175f
- terminal autoreceptor, 98
- thalamic dopamine pathway, 33
- thalamocortical glutamate pathways, 43f, 46
 dopamine pathway to, 26f
 mesolimbic dopamine hyperactivity and, 50f
 sensory filter from GABA neurons, 46, 47f
 dopamine and, 48f
 sensory input inhibition from, 49f
- thioridazine (Mellaril), 85t
- thiothixene (Navane), 85t
- Thorazine (chlorpromazine), 82, 85t
- tics
 dopamine hyperactivity in nigrostriatal pathway and, 31, 32f
- TOH (tyrosine hydroxylase), 20, 20f
- tremor
 as antipsychotic side effect, 95
 nigrostriatal pathway dopamine deficiencies and, 31
- trifluoperazine (Stelazine), 85t
- triglycerides, elevated, atypical antipsychotic agents and, 144f
- tryptophan, 97, 98f
- tryptophan hydroxylase (TRY-OH), 97, 98f
- tuberoinfundibular dopamine pathway, 26f, 32, 32f
 and D2 antagonists, 88f
 dopamine output and, 120f, 132f
 hypoactivity of, 35f
- tyrosine, 20, 20f
- tyrosine hydroxylase (TOH), 20, 20f
 genes for, 73f
- vabicaserin, 201
- varenicline, 203
 dopamine pathway from, 26f, 33
- ventromedial prefrontal cortex (VMPFC),
 dopamine deficit in mesocortical projections to, 28
 mesocortical dopamine pathway to, 30f
 and schizophrenia symptoms, 15, 76f
- verbal abuse, 179
- verbal fluency, impaired, in schizophrenia, 11
- vesicular glutamate transporters (vGluT), 36f, 39, 40f
 dysbindin regulation of, 71
- vesicular monoamine transporters (VMATs),
 and dopamine, 22f
- violence, 10
- Vitamin E
 as free radical scavenger, 196f
- vomiting
 5HT₃ receptors and, 103f
 bifeprunox and, 178
 serotonin receptors and, 99
- waist circumference, monitoring, 146
- weight
 baseline measurement, 149f
 antipsychotic agents and, 143f
 aripiprazole and, 176
 atypical antipsychotic agents and, 137, 140t
 clozapine and, 164
 from histamine-1 receptor blockade, 95
 low risk antipsychotic agents, 140t
 monitoring, 150f
 olanzapine and, 165
 quetiapine and, 169
 ziprasidone and, 171
 zotepine and, 172
- worry, 14. *See also* anxiety
- Y931, 122f
- ziprasidone, 136f, 158, 170, 183
 with 5HT_{1D} antagonist actions, 172
 and cardiometabolic risk, 140t
 dosage with carbamazepine, 161f, 162
 pharmacological icon, 170f
 and sedation, 184, 186f
 and weight gain risk, 140t
- zotepine, 157, 157f, 158, 172
 5HT₆-antagonist properties of, 201
 binding properties, 172f
 dosage with carbamazepine, 161f, 162
 pharmacological icon, 172f
 and QTc prolongation, 171
- zuclopenthixol (Clopixol), 85t